US Stem Cell Inc (USRM)

[saratg]

CAR-T cell therapy technology from Penn State licensed to Novartis and that resulted later in first ever FDA approval of Kymriah in Aug 2017. It’s list price is $475,000.. (Ref: https://medcitynews.com/2018/10/novartis-car-t-likely-improves-log-term-survival-and-is-cost-effective-study-finds/)

USRM has to substantiate their claims with studies and trial data and they will make the cut. If they have substance I’m sure will be a great take over target. This FDA case is all drama by high stake players but the flip side is it can be good test for USRM to validate their claims. If they succeed, o’boy..o’boy.. sky is the limit ??

CAR-T cell therapy: